The study will evaluate the safety and initial efficacy of Adhexil in preventing and/or reducing post-operative adhesions in patients undergoing gynecological surgery of the ovaries.
The clinical trial will be conducted over a one-year period and will enroll 25 patients with bilateral ovarian disease and identified adhesions across four centers in Europe and the US. Adhexil is delivered in a kit containing a human, fibrin-based, absorbable, adhesion barrier. Adhexil can be sprayed on surfaces most at risk for adhesions at the end of the surgical procedure.
Robert Taub, president and CEO of Omrix, said: “This is a significant development for Omrix as it is the first time Adhexil has been used in a clinical setting. Adhexil was developed by Omrix and we believe it holds great promise in its ability to promote post-surgery healing by stimulating the body’s endogenous wound healing mechanisms to prevent adhesions.”